Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Venture Capital
Biotech
Excellergy emerges with $70M and ex-Dermavant CEO at the helm
The California biotech is developing a new drug class in hopes of redefining the standard of care for several allergic diseases.
Gabrielle Masson
Oct 13, 2025 10:50am
Fierce Biotech Fundraising Tracker: Excellergy, Expedition & more
Oct 13, 2025 8:30am
2 ex-Moderna leaders unveil $325M inaugural VC fund
Oct 9, 2025 3:09pm
Expedition resupplies for ph. 2 COPD voyage with $165M series A
Oct 9, 2025 9:50am
Arthrosi raises $153M, fueling dash toward phase 3 gout data
Oct 8, 2025 10:15am
Nilo launches with $101M and mission to harness neural circuits
Oct 8, 2025 9:55am
